Not available
General Information
DRACP ID DRACP01763
Peptide Name Not available
Sequence GTGKA
Sequence Length 5
UniProt ID Not available
PubChem CID Not available
Origin Not available
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
Malme-3M | Melanoma | Carcinoma | As show in fig 8, peptide reduced a size of the tumor due to the cancer cell strains | Tumor growth assay | Not available | Patent |
SNU38R | Melanoma | Carcinoma | As show in fig 8, peptide reduced a size of the tumor due to the cancer cell strains | Tumor growth assay | Not available | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C17H32N6O7
Absent amino acids CDEFHILMNPQRSVWY
Common amino acids G
Mass 50401
Pl 9.7
Basic residues 1
Acidic residues 0
Hydrophobic residues 1
Net charge 1
Boman Index -443
Hydrophobicity -72
Aliphatic Index 20
Half Life
Mammalian: 1.1 hour
Yeast: 3 min
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US2018/0085422A1
Patent Title Compositions for Overcoming Anti-Cancer Drug-Resistance or Compositions for Anti-Cancer Activity Employing Cage-Derived Peptides
Other Iinformation Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Active; Application No: 201514978256; Filed: Dec 22, 2015; Published: Mar 29, 2018; Earliest Priority: Dec 22, 2015; Granted: Jul 21, 2020
Other Published ID US10716826B2